Montag A & Associates Inc. grew its stake in Eli Lilly And Co (NYSE:LLY) by 143.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 93,696 shares of the company’s stock after acquiring an additional 55,180 shares during the quarter. Eli Lilly And Co comprises approximately 0.9% of Montag A & Associates Inc.’s portfolio, making the stock its 27th biggest holding. Montag A & Associates Inc.’s holdings in Eli Lilly And Co were worth $10,055,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC lifted its position in Eli Lilly And Co by 172.9% during the second quarter. FMR LLC now owns 1,188,301 shares of the company’s stock worth $101,398,000 after buying an additional 752,864 shares during the period. We Are One Seven LLC acquired a new stake in Eli Lilly And Co during the third quarter worth about $1,084,000. First American Bank acquired a new stake in Eli Lilly And Co during the third quarter worth about $7,863,000. Greenleaf Trust increased its stake in Eli Lilly And Co by 37.7% during the second quarter. Greenleaf Trust now owns 9,815 shares of the company’s stock worth $838,000 after acquiring an additional 2,686 shares during the last quarter. Finally, Peoples Financial Services CORP. increased its stake in Eli Lilly And Co by 4.7% during the third quarter. Peoples Financial Services CORP. now owns 16,825 shares of the company’s stock worth $1,806,000 after acquiring an additional 750 shares during the last quarter. Hedge funds and other institutional investors own 76.19% of the company’s stock.
In other Eli Lilly And Co news, major shareholder Eli & Co Lilly sold 4,500 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $14.44, for a total transaction of $64,980.00. Following the completion of the sale, the insider now owns 3,915,654 shares in the company, valued at approximately $56,542,043.76. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 202,540 shares of the firm’s stock in a transaction that occurred on Monday, November 12th. The shares were sold at an average price of $113.48, for a total value of $22,984,239.20. Following the sale, the insider now owns 118,814,164 shares of the company’s stock, valued at approximately $13,483,031,330.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,927,900 shares of company stock valued at $140,523,795. Insiders own 0.11% of the company’s stock.
LLY stock opened at $109.81 on Thursday. The company has a quick ratio of 1.53, a current ratio of 1.91 and a debt-to-equity ratio of 0.83. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $116.61. The stock has a market capitalization of $119.92 billion, a PE ratio of 25.66, a P/E/G ratio of 1.81 and a beta of 0.29.
Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter last year, the firm earned $1.05 earnings per share. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. Equities analysts predict that Eli Lilly And Co will post 5.57 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be paid a $0.5625 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.05%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 52.57%.
Several equities research analysts have commented on LLY shares. SunTrust Banks upped their price target on Eli Lilly And Co from $105.00 to $123.00 and gave the stock a “buy” rating in a research note on Monday, October 1st. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, September 28th. Cantor Fitzgerald restated a “buy” rating and set a $128.00 price target on shares of Eli Lilly And Co in a research note on Wednesday, October 17th. TheStreet lowered Eli Lilly And Co from a “b” rating to a “c+” rating in a research note on Friday, August 24th. Finally, JPMorgan Chase & Co. set a $123.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research note on Friday, October 5th. Eight equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Eli Lilly And Co currently has an average rating of “Buy” and a consensus price target of $111.19.
WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/11/15/montag-a-associates-inc-buys-55180-shares-of-eli-lilly-and-co-lly.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: How does inflation affect different investments?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.